| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 72 | 16.8x | 17.8x | Top tier | |
Growth | 70 | 12.6% | 7.1% | Top tier | |
Quality | 94 | 10.9% | 4.5% | Top tier | |
Safety | 65 | 2.0x | 2.6x | Around median | |
Capital Return | 39 | 0.00% | 2.12% | Bottom tier | |
Momentum | 93 | 109.3% | 2.9% | Top tier | |
Sentiment | 45 | 12 | 3 | Around median |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Jazz Pharmaceuticals develops and markets specialized medicines for rare diseases, sleep disorders, epilepsy, and oncology. In Q2 FY2026, revenue was driven by Xywav for sleep disorders, with sales of $471 million, and Epidiolex for epilepsy, with sales of $292 million, alongside an oncology portfolio that includes Zepzelca, with sales of $106 million, Modeyso, with sales of $48 million, and Ziihera, with sales of $15 million. The company is also pursuing growth by expanding indications and dosage forms, such as Epidiolex capsules, and by developing zanidatamab, marketed as Ziihera, in additional tumor types.
Jazz reported record revenue of $1.21 billion in Q2 FY2026, up 16% year over year, including 32% growth in the oncology portfolio, 13% growth in Xywav, and 16% growth in Epidiolex. Net income according to EDGAR data was approximately $192.8 million, and earnings per share were $2.78, while adjusted non-GAAP earnings per share were $5.71, including in-process research and development expenses of $0.94 per share. Adjusted gross margin declined slightly year over year due to higher sales of Zepzelca and Modeyso, which carry third-party royalties.
The results reflect increasing diversification, but Xywav remained the largest individual product and accounted for approximately 39% of Q2 FY2026 revenue. Net income for the twelve months ended in 2026 was approximately $940.8 million on revenue of $4.6 billion, compared with a net loss of $356.1 million on revenue of $4.3 billion in FY2025. The company also generated operating cash flow of $824 million in the first half of FY2026 and repaid its convertible notes due in 2026 during the second quarter.
The average analyst price target is $287.86, within a wide range of $229 to $322, with a consensus Buy rating; the average is approximately 8% above the 52-week range high of $266.38, while the highest target exceeds that high by approximately 21%. This range reflects optimism about the Ziihera approval and growth in Xywav and the oncology portfolio, but the absence of a displayed price-to-earnings multiple and the wide gap between the lowest and highest targets highlight uncertainty surrounding competition in sleep disorders, erosion of Zepzelca's second-line use, and execution of the Actio Biosciences transaction.
Figures in the text are as of 2026-09-02; the live price is shown at the top of the page.
Revenue rose 16% to a record $1.21 billion in Q2 FY2026. Xywav sales grew 13% to $471 million, and Epidiolex sales grew 16% to $292 million, while the oncology portfolio increased 32%. Within oncology, Zepzelca sales rose 42% to $106 million, and Modeyso and Ziihera recorded sales of $48 million and $15 million, respectively.
In August 2026, the FDA approved Ziihera for the treatment of HER2-positive gastric and esophageal cancer, according to the provided news. Phase 3 data showed a 35% reduction in the risk of disease progression or death, while median overall survival with zanidatamab and tislelizumab was approximately 26.4 months, more than seven months longer than with trastuzumab. Jazz enters this expansion with more than 90% overlap among targeted physicians, a permanent J-code, and commercial infrastructure that gained experience as Ziihera reached more than 50% share of the addressable U.S. biliary tract cancer market.
Xywav added approximately 525 net patients in Q2 FY2026, including 200 with narcolepsy and 325 with idiopathic hypersomnia, bringing the total to approximately 17,125 active patients. The patient count grew by more than 12% year over year, and the company raised its outlook for the drug to double-digit growth in FY2026 after adoption of high-sodium alternatives remained limited. However, competition from generic oxybates, orexin therapies, and potential idiopathic hypersomnia products remains a risk, particularly because Xywav accounted for approximately 39% of quarterly revenue.
Automated analysis for informational purposes only — not investment advice.
Epidiolex generated sales of $292 million in Q2 FY2026, with 16% revenue growth and 12% volume growth. The company submitted a new drug application to the FDA for capsules intended to facilitate use among adolescents and adults, without changing ANDA agreements or the protection that management said extends into the late 2030s. It also initiated clinical programs covering Lennox-Gastaut syndrome in adults, developmental and epileptic encephalopathies, and juvenile myoclonic epilepsy, alongside an ongoing trial in focal seizures.
Zepzelca sales grew 42% to $106 million in Q2 FY2026, driven by adoption of first-line maintenance following the IMforte trial. First-line sales accounted for between 30% and 40% of total U.S. sales, and the regimen with Tecentriq received a category 1 listing in the NCCN guidelines. Conversely, Jazz intends to submit a supplement in Q3 FY2026 to remove the second-line indication, and management acknowledged that erosion of second-line sales may accelerate.
On August 12, 2026, Jazz announced an upfront payment of $820 million to acquire Actio Biosciences and obtain ABS-1230 to strengthen its rare epilepsy portfolio. The company had generated operating cash flow of $824 million and held approximately $2.2 billion in cash during the first half of FY2026, and it had repaid its convertible notes due in 2026. Nevertheless, the reported debt burden of $4.4 billion provides a reason to monitor the transaction's return and capital allocation discipline.
